Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

Research and Innovation Action · Running

PEPTAMR Biomimetic antimicrobial peptide inspired by insects to combat multi-drug-resistant Acinetobacter baumannii

Coordinator
Omnix Medical Ltd, Israel
Runs
1 June 2026 to 31 May 2029
Status
Running
EU funding
€7.9m
Total cost
€7.9m
Partners
5 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101287207

What the project is doing

In the project's own words, from its summary on CORDIS.

OMN6 is a synthetic cyclic peptide developed to treat infections caused by multidrug resistant A. baumannii, a WHO critical priority pathogen linked to high mortality. After a clean Phase 1 and an ongoing Phase 2, PEPTAMR moves OMN6 toward late clinical development with the goal of delivering a regulatory-ready Phase 3 packageThe project will expand clinical data collection across Europe, complete the preclinical work needed to justify dosing and indications, run a healthy-volunteer lung penetration study, and finalise a stable, scalable clinical formulation ready for manufacturing.

A companion diagnostic roadmap will be prepared to help clinicians identify patients who can benefit most. Led by OMN with VIV, MUV, NKUA and ECR, PEPTAMR combines industry and academic strengths to produce the assays, models and clinical evidence that will enable licensing and broad hospital use. The ultimate aim is to provide hospitals with a safe, effective, and practical therapy for a deadly, hard to treat pathogen.

Topics

Who is involved

OrganisationCityCountryRole
Omnix Medical LtdJerusalemIsraelCoordinator
Medizinische Universitaet WienWienAustriaParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
VivexiaDijonFranceParticipant
Stichting European Clinical Research Alliance on Infectious DiseasesUtrechtNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI